Deal Watch: GSK Accelerates TCR Collaboration With Adaptimmune

 
• By Ian Haydock, Mandy Jackson, Lisa LaMotta, and Lucie Ellis-Taitt

Merger combines troubled Avalanche's resources with Annapurna's brimming pipeline. Janssen sells its BetaLogic stem-cell IP to partner ViaCyte to hasten development of a stem cell therapeutic for diabetes.

More from Archive

More from Pink Sheet